Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

Johnson & Johnson (NYSE: JNJ) traded lower on Wednesday after the MedTech giant disclosed a temporary pause in U.S. cases treated with its Varipulse Pulsed Field Ablation Platform, which targets ...

“out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. Varipulse cases while it investigates the cause of four reported ...

Johnson & Johnson halted U.S. Varipulse cases after four reported neurovascular events during external evaluation trials. Over 130 U.S. cases and 3,000 global commercial cases have been performed ...

Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ('Johnson & Johnson') (NYSE:JNJ) concerning ...

Johnson & Johnson MedTech has temporarily halted the US rollout of its Varipulse heart device as it investigates four reported stroke events. The suspension, which began on 5 January, affects the ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

In MedTech, J&J's pulsed field ablation system Varipulse will need to prove competitive in the high-growth atrial filbrillation market against offerings from Boston Scientific and Medtronic ...

Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ETCompany ParticipantsJessica Moore - Vice President, ...